Clinical Trial News and Research

RSS

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.

26 Jul 2013

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis vaccine candidate, designed to prevent the deadly parasitic disease.

26 Jul 2013

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Study findings published online, ahead of print, in Cornea show that daily dietary supplementation with a unique combination of omega fatty acids (GLA, EPA and DHA) for six months is effective in improving ocular irritation symptoms and halting the progression of inflammation that characterizes moderate to severe dry eye.

25 Jul 2013

Ascendancy Healthcare signs multi-year collaboration with Quintiles

Ascendancy Healthcare, Inc. dedicated to the commercialization of therapeutic products to meet unmet medical needs in China and other high-growth Asian markets, announced today a multi-year collaboration with Quintiles, the world's largest provider of biopharmaceutical development and commercial outsourcing services.

25 Jul 2013

Artificial pancreas for type 1 diabetes patients: an interview with John Pritchard, Cambridge Consultants

Essentially, what an artificial pancreas would be doing is taking the blood glucose results from a continuous monitor and taking the data that the patient puts in about the amount she/he is eating, and then adjusting the amount of insulin being delivered by the pump based on a mathematical formula that would be very personalized to that patient.

25 Jul 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

PerkinElmer enhances Operetta imaging system to perform live cell assays with higher throughput

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, has announced enhancements for its Operetta® High Content Imaging System, designed to significantly improve the ability of scientists to perform live cell assays with higher throughput, to help foster a better understanding of normal and aberrant cellular behavior.

25 Jul 2013

Manchester scientists treat fatal genetic brain disease using stem cell gene therapy

Scientists from The University of Manchester have used stem cell gene therapy to treat a fatal genetic brain disease in mice for the first time.

From The University of Manchester 25 Jul 2013

Randomized trial examines purging of tumor cells from stem cells prior to transplantation in neuroblastoma patients

Judith Villablanca, MD, of The Saban Research Institute of Children's Hospital Los Angeles, Susan Kreissman, MD, of Duke University Medical Center, and colleagues reported the results of a randomized, phase 3 clinical trial conducted by the Children's Oncology Group examining the effect of selectively removing (purging) tumor cells from blood stem cells before they are transplanted back into patients with high-risk neuroblastoma following high-dose chemotherapy.

25 Jul 2013

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma, a rare form of lung cancer.

24 Jul 2013

Innovative microsurgery technique helps prevent lymphedema in patients with breast cancer

A team of surgeons and members of the breast cancer program of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center is conducting a two-year pilot study of an innovative microsurgery technique coupled with imaging technology to not only prevent lymphedema but also potentially detect and treat it early.

24 Jul 2013

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Back in the early 1960s, just before chemotherapy really started to be used, only about 30% of children survived cancer. That was mainly because they had cancers that were amenable to surgery.

24 Jul 2013

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

The first large non-commercial clinical study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS), shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

24 Jul 2013

Clinical trial finds that sleep quality impacts skin function and aging

In a first-of-its-kind clinical trial, physician-scientists at University Hospitals (UH) Case Medical Center found that sleep quality impacts skin function and aging.

24 Jul 2013

Prana Biotechnology completes PBT2 phase 2 trial in patients with Huntington's disease

Prana Biotechnology today announced the successful completion of Reach2HD, a phase 2 clinical trial in patients with early to mid-stage Huntington disease. The Company expects to announce the results arising from the trial in October.

23 Jul 2013

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Hopes are high for a new and improved tuberculosis vaccine: Serum Institute of India is planning on taking a promising vaccine - originally developed in Germany - and introducing it into the clinical setting.

23 Jul 2013

NF-κB protein complex may boost immune system to eliminate cancerous cells

Researchers at Moffitt Cancer Center and Tianjin Medical University Cancer Institute and Hospital in China have discovered a gene expression signature that may lead to new immune therapies for lung cancer patients.

23 Jul 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives.

22 Jul 2013

IVAN study: Lucentis and Avastin effective in treating wet AMD

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose.

20 Jul 2013

Clinical Trial News and Research

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Ascendancy Healthcare signs multi-year collaboration with Quintiles

Artificial pancreas for type 1 diabetes patients: an interview with John Pritchard, Cambridge Consultants

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

PerkinElmer enhances Operetta imaging system to perform live cell assays with higher throughput

Manchester scientists treat fatal genetic brain disease using stem cell gene therapy

Randomized trial examines purging of tumor cells from stem cells prior to transplantation in neuroblastoma patients

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Innovative microsurgery technique helps prevent lymphedema in patients with breast cancer

Child cancer survival: an interview with Prof Kathy Pritchard-Jones, University College London

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

Clinical trial finds that sleep quality impacts skin function and aging

Prana Biotechnology completes PBT2 phase 2 trial in patients with Huntington's disease

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

NF-κB protein complex may boost immune system to eliminate cancerous cells

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

IVAN study: Lucentis and Avastin effective in treating wet AMD

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer